| 0 (0%) | 11-11 15:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25 | 1-year : | 29.57 |
| Resists | First : | 21.4 | Second : | 25.31 |
| Pivot price | 21.04  |
|||
| Supports | First : | 15.07 | Second : | 12.54 |
| MAs | MA(5) : | 17.89 |
MA(20) : | 21.5 |
| MA(100) : | 19 |
MA(250) : | 59.44 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 27.9 |
D(3) : | 28 |
| RSI | RSI(14): 41.8 |
|||
| 52-week | High : | 138.8 | Low : | 10.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SRPT ] has closed above bottom band by 26.2%. Bollinger Bands are 32.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.15 - 18.3 | 18.3 - 18.4 |
| Low: | 16.96 - 17.12 | 17.12 - 17.23 |
| Close: | 17.06 - 17.31 | 17.31 - 17.47 |
Mon, 10 Nov 2025
Should Investors View Sarepta (SRPT) Differently After ESSENCE Study Details and Q3 Results? - simplywall.st
Fri, 07 Nov 2025
Biggest stock movers Tuesday: PLTR, SRPT, and more - MSN
Thu, 06 Nov 2025
Sarepta (SRPT) Soars 15% on Bullish Rating - Yahoo Finance
Wed, 05 Nov 2025
Guggenheim Maintains Sarepta Therapeutics (SRPT) Buy Recommendation - Nasdaq
Tue, 04 Nov 2025
Sarepta Therapeutics (SRPT): Losses Narrowed 27.2% Annually, Profitability Targeted Despite -13.9% Revenue Outlook - Yahoo Finance
Tue, 04 Nov 2025
Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook - Investor's Business Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 105 (M) |
| Held by Insiders | 8.765e+007 (%) |
| Held by Institutions | 4.6 (%) |
| Shares Short | 20,280 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 663.79 |
| Profit Margin | -2.4 % |
| Operating Margin | 18.9 % |
| Return on Assets (ttm) | -0.1 % |
| Return on Equity (ttm) | -4.8 % |
| Qtrly Rev. Growth | 68.4 % |
| Gross Profit (p.s.) | 1.13028e+009 |
| Sales Per Share | 4.96e+009 |
| EBITDA (p.s.) | 8.03e+007 |
| Qtrly Earnings Growth | 2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -301 (M) |
| PE Ratio | -26.87 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.65 |
| Dividend | 0 |
| Forward Dividend | 1.769e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|